|The City of Hamilton welcomes another investment to the Airport Employment Growth District!
AtomVie Global Radiopharma Inc. (AtomVie), a global leader in the manufacturing and distribution of finished-dose therapeutic radiopharmaceuticals is currently constructing a purpose-built facility for commercial production at 10 Aeropark Blvd. AtomVie is a spinout from the CPDC (Centre for Probe Development and Commercialization, a McMaster Centre of Excellence) located at McMaster University and is now scaling to meet growing demand for the production of radiotherapeutics and medical isotopes.
The new 64,000 sq. ft. state-of-art-facility, leased from Panattoni Development Company, will be finished by 2024 with 10 times more production capacity than AtomVie’s current facility including commercial production. The space will support AtomVie’s activities as a Contract Development and Manufacturing Organization (CDMO) and include laboratories, material storage, a decay room, packaging, and shipping area. Currently, over 10 international pharmaceutical companies are entrusting AtomVie for the clinical supply of their radiopharmaceuticals.
Hamilton has a strong foundation in life sciences and AtomVie’s growth is a testament to how the city is an increasingly favoured destination for nuclear therapeutic companies, which have nearly tripled in the city since 2016. Within Canada, Hamilton is a nuclear medicine hub, housing key assets, such as specialized hot cell labs and reactors that enable the production of goods that are impossible to produce in most other global jurisdictions. Hamilton’s proximity to major international airports and the US border is also a strategic asset for the life sciences sector. AtomVie currently ships the radiotherapeutic drugs it is manufacturing to sites in Canada, USA, South America, Europe, Middle-East, Asia and Australia.
“AtomVie is thrilled to announce the execution of its lease agreement with Panattoni Development Company for its future state-of-the-art facility,” says Bruno Paquin, CEO of AtomVie. “The new facility and its strategic location in Hamilton, Ontario, will firm our position as a global leader in the GMP manufacturing and global distribution of radiotherapeutics for both clinical development and the commercial market, and with the outstanding contribution from our staff, to better improve patients’ lives all around the world”.
The city is proud to support this made-in-Hamilton CDMO which will further anchor the nuclear medicine subsector and foster job growth.
“Hamilton’s world-class reputation in the life sciences sector continues to grow thanks to innovative companies like AtomVie,” says Hamilton Mayor Andrea Horwath. “This home-grown success is proving that Hamilton is the solution to meeting increasing global radiopharma demands. Congratulations to AtomVie for their new facility, and thank you for championing our city and demonstrating how Hamilton is a national leader in research and commercialization.”
“We are excited to see the impressive growth of made-in-Hamilton Radiopharma company – AtomVie which is bolstering the life sciences industry in Hamilton and developing future pathways for export, talent development, research and job creation” says Norm Schleehahn, Director of Economic Development for the City of Hamilton. “We are proud and humbled that AtomVie calls Hamilton home and we are looking forward to witnessing AtomVie’s continued growth and innovation in nuclear medicine.”
About AtomVie Global Radiopharma Inc.
AtomVie, officially launched in August 2022 with its successful closing of series A funding by Avego of $40M, is a global leading CDMO for the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals and figures as the most recent spinout from the CPDC. Founded in 2008, the CPDC is a CECR (Centre of Excellence for Commercialization and Research) created with the long-time support from the NCE (Networks of Centres of Excellence), McMaster University and the OICR (Ontario Institute for Cancer Research). The expertise developed at the CPDC and its reputation as high-quality radiopharmaceutical CDMO is the stepping stone for the AtomVie spinout. AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves 10 international clients with 12 clinical studies with sites in over 17 countries worldwide. For more information about AtomVie, visit www.atomvie.com or contact: email@example.com.
About Hamilton Economic Development
Hamilton’s Economic Development Office is the central point of contact for business assistance. Its services are geared to serve new start-up companies, corporate relocations, and the expansion and retention of existing business. Its mission is to serve as the catalyst for continued economic growth, job creation, and revitalization in Hamilton. Visit investinhamilton.ca for more information.
For more details on 10 Aeropark Blvd. visit: 10 Aeropark Blvd is Now Fully Leased! | Panattoni Canada